---
category: disclosure
circular_id: 5c80dce4b566bec2
date: '2025-08-01'
description: Lupin Limited and Sun Pharmaceutical clarify they did not receive letters
  from US President regarding drug pricing as reported in media.
draft: false
guid: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={7F013B62-C7E0-4E4E-8140-D6DE5D984C34}&noticeno=20250801-65&dt=08/01/2025&icount=65&totcount=73&flag=0
impact: low
impact_ranking: low
importance_ranking: low
justification: Routine clarification response to media reports with no material impact
  on companies
pdf_url: https://www.bseindia.com/markets/MarketInfo/DownloadAttach.aspx?id=20250801-65&attachedId=a85e14af-98d9-48af-a5af-bef625026bf5
processing:
  attempts: 1
  content_hash: 3025d61056032892
  processed_at: '2025-08-01T15:25:11.110769'
  processor_version: '2.0'
  stage: completed
  status: published
published_date: '2025-08-01T13:53:53+00:00'
rss_url: https://www.bseindia.com/markets/MarketInfo/DispNoticesNCirculars.aspx?Noticeid={7F013B62-C7E0-4E4E-8140-D6DE5D984C34}&noticeno=20250801-65&dt=08/01/2025&icount=65&totcount=73&flag=0
severity: low
source: bse
stocks:
- LUPIN
- SUNPHARMA
tags:
- clarification
- media-response
- pharma
- us-pricing
- disclosure
title: Clarifications received from companies regarding Trump pharma price letters
  news
---

## Summary

Two pharmaceutical companies, Lupin Limited and Sun Pharmaceutical Industries Limited, have issued clarifications in response to exchanges' queries about a news report claiming President Trump sent letters to 17 global drug majors seeking lower prices. Both companies confirmed they did not receive any such letters and stated there is no material impact on their operations.

## Key Points

- Lupin Limited confirmed it has not received any letter from the US Government regarding drug pricing
- Sun Pharmaceutical Industries Limited also confirmed it is not among the recipients of any such letter
- Both companies stated they are not aware of any undisclosed information that could explain trading movements
- The news report was general in nature and not company-specific
- Companies clarified there is no material impact on their business operations

## Regulatory Changes

No regulatory changes mentioned in this circular.

## Compliance Requirements

- Companies responded to stock exchange queries under Regulation 30 of SEBI Listing Regulations
- Both companies reaffirmed their commitment to making prompt disclosures of material information

## Important Dates

- August 01, 2025: Date of clarification letters from both companies
- July 31, 2025: Date when US President reportedly sent letters to pharmaceutical companies

## Impact Assessment

Minimal impact as both companies confirmed they were not recipients of any US government letters regarding drug pricing. This was a routine clarification exercise in response to media reports that caused market speculation. No operational or financial impact expected on either company.